**REGISTERED COMPANY NUMBER: 02854091 (England and Wales) REGISTERED CHARITY NUMBER: 1029318** 

**REPORT OF THE TRUSTEES AND** 

**AUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD 1 MAY 2024 TO 31 MARCH 2025** 

**FOR** 

**TAMESIDE & GLOSSOP HOSPICE LIMITED (A COMPANY LIMITED BY GUARANTEE)** 

Moss & Williamson Limited Chartered Accountants Statutory Auditor Booth Street Chambers Ashton-under-Lyne Lancashire OL6 7LQ 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **CONTENTS OF THE CONSOLIDATED FINANCIAL STATEMENTS for the Period 1 May 2024 to 31 March 2025** 

||**Page**|
|---|---|
|**Reference and Administrative Details**|1 to  2|
|**Report of the Trustees**|3 to  15|
|**Report of the Independent Auditors**|16 to  18|
|**Consolidated Statement of Financial Activities**|19|
|**Consolidated Balance Sheet**|20|
|**Company Balance Sheet**|21|
|**Consolidated Cash Flow Statement**|22|
|**Notes to the Consolidated Cash Flow Statement**|23|
|**Notes to the Consolidated Financial Statements**|24 to  40|





**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

**REFERENCE AND ADMINISTRATIVE DETAILS for the Period 1 May 2024 to 31 March 2025** 

**Registered Company number** 02854091 (England and Wales) 

**Registered Charity number** 1029318 

## **Registered office** 

Willow Wood Close Ashton-under-Lyne OL6 6SL 

## **Patrons** 

Justin Moorhouse Julie Hesmondhalgh Sharman Birtles MBE Philip Cowper Julie Goodyear MBE Brian Wild Tafheen Sharif Ellie Leach 

**President** Martin Willescroft 

**Chair** Timothy Jackson 

## **Senior Management Team (Non-Director/Trustees)** 

Chief Executive: Director of Fundraising & Communications: Clinical Director: Director of Finance: Head of HR and Workforce: 

Tracy Minshull Sam Duncan Nicola Cheetham Ian Wicks Gill Egerton 

## **Trustees** 

M J Willescroft J H Maltby S Flanagan E Needham P J Millson T Jackson P Schofield J Ormston (Resigned 09.09.2025) P Brown (Appointed 28.01.2025) K Richardson (Appointed 28.01.2025) C Hinds (Appointed 28.01.2025) J Carter (Appointed 28.01.2025) (Resigned 20.06.2025) F Bokhari (Appointed 01.09.2025) S Giblin (Appointed 01.09.2025) 

Page 1 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

**REFERENCE AND ADMINISTRATIVE DETAILS for the Period 1 May 2024 to 31 March 2025** 

## **Auditors** 

Moss & Williamson Limited Chartered Accountants Statutory Auditor Booth Street Chambers Ashton-under-Lyne Lancashire OL6 7LQ 

## **Solicitors** 

Thompson & Cooke 12 Stamford Street Stalybridge Cheshire SK15 1LA 

## **Investment Managers** 

Rathbones 3 Hardman Street Spinningfields Manchester M3 3HF 

## **Principal Bankers** 

NatWest Bank PLC Warrington Street Ashton-under-Lyne Lancashire OL6 6JL 

Page 2 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **REPORT OF THE TRUSTEES** 

**for the Period 1 May 2024 to 31 March 2025** 

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the consolidated financial statements of the charity for the period 1 May 2024 to 31 March 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019). 

We are pleased to present our report and the audited consolidated financial statements of the company Tameside & Glossop Hospice Limited (known throughout the region as Willow Wood Hospice) for the period ended 31 March 2025. 

Willow Wood Hospice is an independent, charitable voluntary body, funded in the main by the generosity of our local community of Tameside & Glossop. 

Willow Wood opened its doors in 1999 and celebrated 25 years in 2024. The hospice places great value on its connections and working relationships with our Integrated Care Board (ICB), local NHS Foundation Trust, the local Council and local businesses. 

Our driving force is that a hospice is not just a building but a whole philosophy, incorporating care, love and understanding for patients and their carers. We aim to provide high quality care ensuring comfort and personal dignity at all times. 

Page 3 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **REPORT OF THE TRUSTEES for the Period 1 May 2024 to 31 March 2025** 

## **OBJECTIVES AND ACTIVITIES** 

## **Our aims and objectives** 

We aim to continue to be a leader in the development of Hospice and Palliative Care, providing excellence in quality care to the people of Tameside & Glossop. 

## **Our mission** 

Our mission is to lead and deliver high-quality specialist palliative and end-of-life care, support and education across Tameside and Glossop. 

## **Our values** 

- **C** ompassion -  to those we support 

- **A** ccountable 

- **R** espectful 

- **E** xcellent 

- for our actions 

- of each other 

- when we collaborate, innovate and educate 

## **Our philosophy** 

A hospice is not merely a building, but a philosophy that incorporates care, love, and understanding. At the heart of this philosophy is the patient, where care is tailored to meet individual needs and wishes throughout the changing phases of their illness. It is our mission to support not only the patients, but also their families and carers, fostering a sense of dignity, comfort, and peace during what can be a difficult time. 

Our goal is to ensure that patients achieve the best quality of life possible, with compassionate care that meets both physical and emotional needs. This includes providing the time and space for mental and spiritual preparation for death, in a way that feels right for the individual and their loved ones. 

However, over the past three years, we have faced significant financial challenges. The absence of a national funding model for hospices, combined with rising costs - particularly in areas such as national insurance, salary expenses, and the ongoing cost of living crisis - has placed considerable strain on our ability to meet the increasing demand for services. 

Currently, our hospice receives just 23% of its funding from NHS contributions (compared to the national average of 31%, as per the 2022 Hospice UK Accounts Report), and even less than other hospices in the Greater Manchester region. This funding model is not sustainable, and it underscores the need for a fairer, more sustainable approach to hospice care funding in the future. 

This year, we need to raise £3.2M in addition to the ICB Grant to continue delivering the high-quality care our patients and their families rely on. In parallel, we will continue to lobby local Integrated Care Boards and MPs for a more equitable funding model. Through collaboration with our Greater Manchester partners, we hope to create a future where funding follows service transformation, ensuring that hospices like ours can continue to serve our communities with compassion and dignity for years to come. 

The current national funding model for hospices is not sufficient to meet the growing demand for services, and unfortunately, it remains inadequate in terms of fully supporting our vision and mission. As we prepare for the 2026-2027 fiscal year, we are once again facing the reality of a deficit budget. In response to this ongoing financial challenge, we introduced our Sustainability Plan 2025-2028 in 2025. This plan is designed to help us manage budgetary pressures, and if necessary, to restructure and redesign our services to ensure we can continue to deliver the high-quality care our patients and families rely on. 

Despite these challenges, we remain focused on our vision for the future. We are committed to exploring new opportunities to expand our reach into local communities, ensuring that our services are accessible to those who need them most. In addition, we have made a strategic investment in our income generation and marketing team, strengthening our ability to fundraise and secure the remaining 77% of our funding that is essential to our operations. 

Page 4 



## **TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **REPORT OF THE TRUSTEES for the Period 1 May 2024 to 31 March 2025** 

This is a time of transformation for our hospice, and while the road ahead may be challenging, we are determined to navigate it with resilience, innovation, and a deep commitment to the people we serve. With the continued support of our community, partners, and donors, we believe we can build a sustainable future for our hospice that ensures care and compassion are never compromised. 

## **CHARITABLE PURPOSE** 

## **Delivering public benefit** 

Willow Wood Hospice is an independent charity that provides, free of charge, palliative and end of life care to patients with life limiting illnesses, with the aim of helping each individual attain the best quality of life (regardless of race, gender, disability, age, colour or religion) by providing the highest standard of holistic care in a warm, friendly environment. The care offered also extends to patient families, carers and close friends during illness and continuing after bereavement. Willow Wood Hospice is regulated by the Care Quality Commission (CQC), the independent regulator of health and social care in England. 

A meaningful indication of our public benefit activities is demonstrated in the following review of our achievements and performance. Additional evidence comes from the response we receive from the Tameside and Glossop community we serve. Over the 25 years since the Hospice first opened its doors, we have become a valued and important part of the community, receiving hundreds of comments and letters of appreciation. We welcome all forms of feedback and use it continuously to enhance the quality of every aspect of the services we provide. 

We continue to improve and grow through continually assessing the needs of our community and working proactively in ensuring that our services are in line with both community and government recommendations. Working closely with other local service providers, we undertake projects that not only help us provide the best end of life care for patients and their families, but also help to reduce the burden on the NHS. 

Hospices throughout the UK are already leading a range of initiatives that seek to either prevent avoidable admission to hospital for people approaching the end of life, or facilitate the appropriate and timely transfer of hospital patients who have no clinical need or do not wish to be in a hospital bed at the end of life. 

We have referred to the Charity Commission's general guidance on public benefit when reviewing our aims and objectives and in planning our future activities. 

## **Objectives and activities** 

Our four strategic priorities are: 

## **1) Communication** 

We will prioritise strengthening internal communication, external communication, and community engagement, as well as branding and identity to ensure we have an impact on all stakeholders. 

## **2) Quality of Care** 

Our focus will be on the care and experience patients receive, support for families and carers, a commitment to excellence and improvement as an organisation, and valuing recognition and feedback. 

## **3) People** 

Our strategy places people at the heart of our vision, focusing on leadership and management, nurturing a supportive and inclusive team culture, and workforce development and education. 

## **4) Sustainability** 

Our strategy emphasises sustainability through robust income generation, effective financial management, strong governance and rigorous quality control to secure the hospice's long-term future. 

Page 5 



## **TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **REPORT OF THE TRUSTEES for the Period 1 May 2024 to 31 March 2025** 

## **ACHIEVEMENTS AND PERFORMANCE 2024/2025** 

Our teams provide a wide range of services, delivering holistic, personalised, and compassionate care that supports patients, families, and carers to maintain wellbeing, dignity, and confidence in the care they receive. 

## **In-Patient Unit (IPU)** 

Our Inpatient Unit operates up to 10 en-suite bedrooms, including two larger rooms to accommodate families or patients requiring specialist equipment, enhancing the overall patient and family experience. The unit provides tailored care and support for patients living with terminal conditions such as cancer, motor neurone disease, chronic respiratory or cardiac illnesses, Parkinson's disease, and end-stage dementia. 

Our compassionate, multidisciplinary team works together to ensure patients with specialist palliative care needs can maximise quality of life through pain and symptom management, emotional and spiritual support, and safe, timely discharge to home or continuing care services. We also provide a supportive environment for patients and families at the end of life. 

This year, our focus has been on maintaining capacity within the IPU in response to continued high demand, ensuring that patients and families have access to the care they need when they need it most. 

## **Data for 2024/2025:** 

207 inpatient admissions, 30 discharges, 178 deaths with 8 patients in the hospice at the year end. 

Average bed occupancy was 79% (bed numbers reduced due to staffing shortages).  Average length of stay was 9 days. 

## **Community Services** 

This year, we continue to deliver around 70% of care within community services, including group therapy sessions in our welcoming lounge, The Hive. Following last year's revision of our support programme post-pandemic, our focus has been on working more collaboratively, improving pathways into our services, and extending engagement across the community. 

To lead this work, we have introduced the role of Head of Community Services, strengthening coordination and oversight as we continue to bring all community services together. 

## **Wellbeing** 

Our Wellbeing Service provides emotional and psychological support to adults with a life-limiting diagnosis, offering both group and individual sessions led by experienced healthcare professionals. The service is designed to empower patients and families to live well with their illness, enhancing wellbeing, improving physical function, and providing emotional support. Sessions take place in The Hive, and in our gardens, with medical support available as required. 

Patients and families have consistently provided positive feedback, highlighting the value of the service in helping them manage their illness and maintain quality of life. Referrals can be made by healthcare professionals or via self-referral. 

## **Complementary Therapies** 

Our experienced complementary therapist, supported by trained volunteers, offers individual therapies including reflexology, reiki, massage, and relaxation to both wellbeing patients and inpatients. This year we have focused on making these therapies available earlier in the care journey and on the inpatient unit, ensuring patients and carers can access support when they need it most. 

These therapies promote relaxation, balance, and a sense of wellbeing, helping to optimise quality of life for patients and offering valuable support to those caring for them. 

Page 6 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **REPORT OF THE TRUSTEES for the Period 1 May 2024 to 31 March 2025** 

## **Data for 2024/2025:** 

154 new referrals, 87 added to caseload, 343 complementary therapies (patient and carer), 414 contacts via groups. 

## **Therapy** 

Our therapy team, including physiotherapy and occupational therapy, supports people living with life-limiting illness to maintain independence, manage symptoms and enhance quality of life, whether at the hospice or in their own home. Working closely with other professionals, the team provides rehabilitation, education and advice, supports future care planning and helps patients work towards meaningful personal goals. 

This year we have strengthened our community connections, especially in relation to equipment provision and community specialist palliative care teams. 

## **Data for 2024/2025:** 

320 New referrals, 248 added to caseload, 497 number of home visits. 

## **Dementia** 

Willow Wood's Dementia Care Service continues to support people living with advanced dementia and their families, primarily in the last year of life. This year we have increased support for people living at home and strengthened our work across nursing and care homes, ensuring care is delivered within familiar environments. 

The service works closely with a wide range of professionals, and we have further enhanced our links with local Admiral Nurse teams and mental health services to provide more coordinated, specialist input. 

We also continue to offer therapeutic group sessions for carers. Delivered in partnership with the Family Support, Bereavement, and Dementia Teams, the Dementia Carers Support Group provides a safe space to share experiences and coping strategies over an eight-week programme. 

## **Data for 2024/2025:** 

127 New referrals to service, 594 Follow up assessments, 718 Home visits, 24 Café Groups. 

## **Family Support** 

Our team remains committed to providing emotional, psychological, and spiritual support to patients and their families. This year we have expanded our offer to include more group-based therapeutic support and introduced responsive "in-the-moment" sessions to meet needs as they arise. 

We have also strengthened the service through new volunteer roles, particularly in spiritual support, and by increasing volunteer and student counsellor placements. These developments enhance the support available while helping us grow and develop our future workforce. 

## **Data for 2024/2025:** 

193 Adult Referrals: 113 assessed 

13 individual children and young adults (3-18 years) accessed the bereavement services 

Total Counselling Sessions (following assessment) 658, 60 ad hoc single sessions. 

Total number of support groups held: 26 

Page 7 



## **TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **REPORT OF THE TRUSTEES for the Period 1 May 2024 to 31 March 2025** 

## **QUALITY AND GOVERNANCE** 

Trustees and Senior Management recognise the importance of committing to ensuring the delivery of high-quality clinical care and promoting patient safety within the hospice. The investment in a new role of Quality, Governance and Compliance Lead in the financial year (2026) will help to ensure the hospice commits to a quality improvement culture and adheres to a statutory regulation culture, as well providing advice on and developing the hospice's compliance with CQC regulations in relation to legislation and best practice, ensuring that high standards are maintained. This role feeds into our Clinical Governance Committee. 

## **Clinical Governance** 

Our Clinical Governance Committee is a subcommittee of the Board of Trustees, chaired by our Chairman. Its purpose is to provide assurance that our services are safe, effective, well-led, and responsive, while supporting sustainability, accessibility, and regulatory compliance. The Committee drives clinical strategy, patient safety, and continuous improvement, reviewing, challenging, and guiding operational delivery. 

The Clinical Director chairs and participates in the operational committees - the Multi-Professional Leadership Meeting and the Clinical Quality and Standards Meeting - which feed into the Clinical Governance Committee. These meetings cover key areas including incidents and risk management, audits and monitoring, medicines management, infection control, falls and pressure area care, compliments and complaints, and initiatives to enhance patient, carer, and staff experience. 

This year we have strengthened partnerships with Tameside & Glossop ICFT, Supportive Care UK, and GTD Healthcare, supporting a more diverse and capable workforce while maintaining safe, effective services. We remain committed to national frameworks, including the Patient Safety Incident Response Framework (PSIRF), promoting a culture of openness through Freedom to Speak Up, and connecting with the local system quality group to align with wider health and social care quality standards. 

## **Education** 

This year we have focused on developing and implementing a flexible train-the-trainer model across many areas such as moving and handling, that enables clinical champions to support learning within their own teams and sustain competencies. In collaboration with Workforce Development, we have strengthened a cross-organisational approach to education, promoting consistency and shared best practice across the whole workforce. 

We have also delivered external training, further supporting our community to care and learn from each other also raising the profile of hospice care. 

In addition, we have continued to enhance the student experience, welcoming a broader range of learners from different disciplines and increasing the number of student placements. These developments further reinforce our learning culture and support the future workforce of our future. 

## **Staffing** 

The hospice employs a diverse and immensely skilled workforce across a number of business areas, which we work hard to retain and support through development and commitment. To enable us to recruit into Clinical roles at the hospice, for our clinical staff we continue to mirror the salary framework and pay structure of that of the NHS. All other staff are paid in line with the industry pay levels and within the budget restraints of the Charity whilst also fulfilling all legal requirements of pay including the annual increase to the minimum wage.  A remuneration team within the HR committee meets to discuss the annual pay awards and makes recommendations into the Finance Committee and the wider Board. 

Page 8 



## **TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **REPORT OF THE TRUSTEES for the Period 1 May 2024 to 31 March 2025** 

Staff engagement sessions have now been in place within the hospice since the middle of 2024.  These quarterly face to face sessions have proven invaluable in developing the hospice strategy and afterwards actively working to really bring this to life.  Staff surveys are undertaken by an external company Birdsong as well as with internal "temperature checks".  These results allow us to gather insight into what is important to our employees and to have a measure of their engagement.  It also gives them the opportunity to know their opinions are valued and for us to identify any early warning signs of issues may arise. The Birdsong survey is benchmarked with industryspecific data.  The results of our most recent survey had some pleasing figures and in relation to engagement, 95% understand and believe in the aims of the charity. 

Our staff turnover remained stable at 17% for the 12-month period, a small change from 16% in the year before. Absence due to sickness is monitored closely and actively managed. Sickness is 3.8% for the year, the vast majority of which was as a result of a small number with long term sickness, against a figure of 5.8% in health care in the North West of England. 

Overall, staff engagement remains high and we continue to shape our staff strategy to and new initiatives to maintain this. 

## **Volunteers** 

The largest workforce throughout Willow Wood is our dedicated volunteers who play a vital role in the day-to-day operations of hospice work, including its lottery and retail operations.  It is recognised that the partnership we have with volunteers is vital to the success of the hospice and without whom we would not function. 

We have 463 active volunteers at April 2025 saving the hospice over £1M per year in salaries. In addition to the individuals who volunteer for us, we have increased numbers of individuals from Tameside College and Ashton Sixth Form College who have been gaining work experience to support their learning and we also have a number of companies who now regularly support us on volunteer days at Willow Wood.  As with our staff, volunteers have an equally diverse range of skills. Trustees are committed in ensuring that those skills are utilised to the benefit of the Hospice and to the individual. 

Considerable work has taken place to look at our volunteer workforce and our staff workforce as one, wherever possible.  As such, the workforce engagement sessions that have been underway since 2024 have been made up of both paid staff and volunteers, working together.  The engagement from these groups remains high and the opportunity to work with individuals, students and corporate volunteers has allowed us to truly utilise unpaid hours to support and drive the continuous improvement of the hospice. 

## **Income Generation** 

The ongoing support of our local community, together with their generous responses to appeals and campaigns, remains vital to our success. The trust we have built with our supporters, reinforced by consistent engagement through regular communications and social media, continues to play a central role in our achievements. The introduction of our new event, the Enterprise Challenge, has been a notable addition to our fundraising calendar and has already demonstrated strong potential. Alongside this, the continued growth of the Bunny Hop, raising an impressive £40,000 this year, highlights the increasing engagement of our community and the effectiveness of our evolving events programme. 

Our hospice retail operations have also continued to flourish. This year, we celebrated the opening of a Clearance Outlet within our distribution centre, which is already performing strongly. This notable milestone reflects the dedication and hard work of our retail employees and volunteers, whose commitment has been instrumental in driving this progress. 

Page 9 



## **TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **REPORT OF THE TRUSTEES for the Period 1 May 2024 to 31 March 2025** 

## **Code of Fundraising Practice** 

Willow Wood Hospice is fully registered with the Fundraising Regulator and adheres to all relevant standards outlined in the Code of Fundraising Practice, including safeguarding vulnerable individuals. This report outlines the key requirements that charities must follow as specified in the Charities Act 2016. We exclusively partner with professional fundraising agencies that can demonstrate a proven track record of adhering to best practices in the sector and complying with the Fundraising Regulator's guidelines 

To ensure compliance with the General Data Protection Regulation (GDPR), we regularly review our policies and procedures relating to personal data. We rely on legitimate interest as the legal basis for processing data and follow the principle of only communicating with supporters about activities we believe would be of interest to them. We provide all supporters with clear and simple opportunities to update their communication preferences at any time. Additionally, no complaints were received through other channels. 

Page 10 



## **TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **REPORT OF THE TRUSTEES for the Period 1 May 2024 to 31 March 2025** 

## **FINANCIAL REVIEW** 

The accounts for the year have been prepared in accordance with the Statement of Recommended Practice - 'Accounting and Reporting by Charities' SORP 2019 and comply with all statutory requirements and the governing document of the hospice. The company meets the definition of a medium-sized company and so we have adopted FRS 102 when preparing the accounts. 

During this period the Company changed its year end to the 31 March 2025 and this period is a shortened 11-month period. 

The Consolidated Statement of Financial Activities (SOFA) is on page 19 of these financial statements. The Company has made an operating deficit in the 11 months to 31 March 2025 (before unrealised gains/losses on investments) of (£814,752) (2024 surplus of £272,916). After adjusting for unrealised gains/losses on investments, the deficit for the 11 months was (£777,482) (2024 surplus £338,906). 

The overall level of income for the 11 months is significantly down on the previous year at £3,582,499 (2024: £4,775,205). The main reason for the reduction in income is that legacies receivable in the accounting period were down by over £1.1M on the previous year after the previous year’s £1M increase. The differences in legacies between the years highlight how this source of income cannot be relied on at the moment for sustainable income. Donations from individuals, trusts and In Memoriam donations are however up in this 11-month period. As stated above, the income transferred from the Trading Company WWHP is down for this 11month period mainly in the area of Lottery income. 

During this financial period, the level of funding from the Integrated Care Boards for Greater Manchester and for Derby and Derbyshire (the two funding Authorities that took over from Tameside and Glossop Clinical Commissioning Group (CCG)) was virtually unchanged from the previous year and down on an actual basis due to the shortened period. The increase in grants seen within the Accounts is mainly due to the fixed Central Government grant announced by the Government in late 2024 and a 6-month one off boost from the ICB covering the period to 30 September 24.  For the 11 months to 31 March 2025 we received £840,671 (2024: £677,648). The ICB grant is the only regular public funding received by the Hospice towards its medical and running costs (we receive a separate Grant for a proportion of our Dementia service costs). The ICB grant (excluding the Capital and one-off grant) now represents 19.94% (2024: 20.71%) of total Hospice expenditure. These percentages are of total Hospice Expenditure where as in negotiations with the GM ICB some of our costs are disallowed in there considerations and the 2025 agreed percentage on allowable expenditure was 23.69%. This is well below the NHSE guideline figure of 33% of expenditure and we remain in negotiations with GM ICB to move toward this figure. The percentage of our costs covered by the grant has gone down this year due both to the small increase in the grant and to the increases in costs (described below) during the year, leading to the increases in pro rata Hospice costs as set out below. 

The grant income together with the net income (Deed of Covenant) from our Trading Subsidiary, WWHP, this financial year accounts for 34.82% (2024: 35.22%) of the hospice and fundraising expenditure. The decrease is mainly due to the increase in pro rata expenditure in areas such as Payroll and Utility costs and a decrease in this year in the Deed of Covenant transfer from WWHP. Against this there is a modest increase in grant income due to the government grant for Capital projects. 

Total expenditure during the 11 months to the new year end was £4,397,251 (2024: £4,502,289) including restricted fund expenditure. Although a there is a reduction in expenditure it must be remembered we are comparing an 11-month period with a 12-month one. There are a number of cost headings that are actually higher on a monetary basis, particularly utility costs, postage and portfolio management fees (due to the change in period and the accrual of year end fees. In addition, there are a number of areas that would have been higher based on pro rata expenditure, particularly payroll. 

Page 11 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **REPORT OF THE TRUSTEES for the Period 1 May 2024 to 31 March 2025** 

## **Investment policy** 

The investment policy is reviewed periodically through the Investment/Finance subcommittee and any amendments would be submitted to the Board for approval. It is the charity's policy to specifically exclude investing directly in tobacco manufacturing companies and any decisions regarding investment are undertaken after taking appropriate advice from professional advisers. No changes were made to the Policy during the Financial Year. 

This year we have continued with our policy of concentrating any new investments in Fixed Interest Deposits with major financial institutions due to continued market uncertainties. However, Willow Wood continues to invest a proportion of its funds in Equities managed externally by professional fund managers. 

No new money was invested in the Equity portfolio during the 11 months other than all dividends and interest received on the portfolio and any Gains on disposals during the year are used to settle management fees and the balance is reinvested in new equity investments. 

The book cost of investments as at the period-end was £1,827,163 (2024: £1,812,145). Compared with this the market value at the period-end date stood at £2,107,636 (2024: £2,055,348). The latest Valuation provided (and reconciled) for the Investment/Finance subcommittee was £2,376,632 at the 30 September 2025 (£2,107,407 at 31 October 2024). 

## **Reserves policy** 

As an organisation, we are aware that as more people live longer, it is likely they will experience multiple complex health needs and that there will be a significant and steady increase in the growth in demand for both palliative and end of life care. Willow Wood Hospice has an essential role to play in helping to meet this demand and we need to ensure that we have the resources in place to facilitate this. 

With our high dependency on voluntary donations and legacies, the Trustees consider it essential to have reserves. The aim is to hold at least 12-months running costs in General Unrestricted Reserves. At the balance sheet date, we fell just short by £110,000 on Company expenditure (excluding the Trading Company) or £420,000 when adjusted for the 11-month period. 

However, we should differentiate between Free Reserves and Total General Reserves. General Unrestricted funds at the Company Balance Sheet date were £3,304,420 (2024: £4,091,581) or 11.6. months based on the 11 months (2024: 14 months) of current year expenditure. This decrease in months of coverage is due to the deficit in the period despite the reduction in income (due to the shorter period). If we look at cash and other liquid assets only, (Free Reserves), as distinct to total Unrestricted Reserves which include Fixed Assets and Investment properties, these stood at the Company Balance Sheet date at £2,736,252 (2024: £2,966,224). Of this amount £980,615 (2024: £970,975) have already been designated by the Trustees leaving a balance of £1,755,637 (2024: £1,995,249). These amounts represent 6.17 months (2024: 6.81 months) of Hospice Expenditure (based on the shorter period). In addition to the General Reserve an Asset Replacement Reserve is maintained as detailed in the accounting policies on page 25 to be used against the schedule of work to the hospice advised by an external review of the hospice premises. 

As stated above, Tameside & Glossop Hospice draws the bulk of its income from the public with only 26.2% (2024: 20.09%) of company General Income coming by way of the Core Annual ICB (previously CCG) grant. The increase in the proportion this year is due to the reduction in income from other sources (namely Legacies during this year) and not because of any increase in the Core grant from the ICB. The uncertainty attached to our various income streams, particularly in terms of legacies, donations and fundraising events, necessitates that we hold substantial reserves. In light of the current turbulent economic situation (brought about by economic uncertainties, the cost of living crisis, the war in Ukraine, rising electricity and gas prices and the impact on people's disposable income), future income for the hospice remains uncertain. The medium to long term impact on Income (and ultimately reserves) must await events outside our control in respect of the impact that any Climate Change restriction and the ongoing economic uncertainties may have on the financial situation of the country and hospice. 

Page 12 



## **TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **REPORT OF THE TRUSTEES** 

**for the Period 1 May 2024 to 31 March 2025** 

## **Asset replacement reserve** 

The 2011 asset replacement provision totalled £437,001. Following a review of the basis of the provision, after the completion of the new hospice wing and refurbishment of the existing building, the total provision did not materially differ to this amount at the time. The Trustees decided therefore that no major adjustments were necessary. Following the replacement of many of our assets, the provision has been enhanced this year by a further £5,000 and at the year-end stood at £512,000. The current year movement on the provision is included within the transfer between funds in note 21. 

## **Future plans** 

A new strategic business plan was developed during 2024, setting out our priorities for the next five years. Insights from our workforce engagement sessions have played a key role in shaping this strategy, which will be supported by a robust implementation and delivery plan. 

Our strategy reflects our commitment to providing excellent care while adapting to future challenges and opportunities. It focuses on supporting and developing our workforce - our staff, volunteers and trustees - so they feel valued and equipped to thrive. We are dedicated to creating an inclusive environment where everyone feels welcome and respected. 

We are currently facing financial challenges which will impact our ability to provide the care our community relies on, if those challenges are not addressed. We will continue to work with our MPs, partners and Hospice UK to help secure fair, sustainable funding for the long term. Sustainable fundraising and income generation are key to securing our future, along with using digital technology to enhance how we connect with and care for those who need us. 

Local and national challenges will shape our growth and development - our strategy reflects this. We are committed to contributing to the local healthcare system to drive improvements so that our community benefits. At the same time, our population is growing and has more complex health needs, meaning our services must evolve to meet these demands. 

To continue delivering high-quality care, we will focus on improving our services through quality assurance, supported by education and training. We will also strengthen our local and national partnerships to better support our patients and those closest to them. 

This strategy is our plan for meaningful progress over the next five years. By working together with our workforce, supporters and partners, we will rise to the challenges and continue to deliver the high-quality, specialist care that defines Willow Wood Hospice. 

Page 13 



## **TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **REPORT OF THE TRUSTEES for the Period 1 May 2024 to 31 March 2025** 

## **STRUCTURE, GOVERNANCE AND MANAGEMENT** 

## **Governing document** 

The organisation is a charitable company limited by guarantee, incorporated on 16 September 1993, operating as Willow Wood Hospice. The Company was formed under a Memorandum of Association, which established the objects and powers of the charitable company and is governed under its Articles of Association. 

The Company operates a wholly owned subsidiary trading company known as Willow Wood Hospice Promotions Limited. 

## **Trustee council of management** 

Members of the Council of Management, who are directors for the purpose of company law and Trustees for the purpose of charity law, who served during the year and up to the date of this report are shown on page 2. This report lists the Charity Trustees at the balance sheet date and those who had held office during the year; they are all members of the Council. The Company is a company limited by Guarantee with up to 30 members following a change at the AGM of November 2019. The Trustees are elected by the members at the Annual General Meeting to serve a term of three years. One third of the Trustees retire annually but may currently offer themselves for reelection by the members. The Statutory rules of the Company/Charity are currently under review and any suggested changes will be put to the Trustees for consideration. 

## **Trustee recruitment, induction and training** 

The Board endeavours to ensure the make-up of its membership reflects the needs of the hospice and the community it serves in providing a mix of professional skills necessary for the day-to-day and long term running of the Charity. The skills of our current panel of Trustees include clinicians, legal, architectural, human resources, employment law, health and safety, communications and general professional management. 

The organisational structure means the Board of Trustees is responsible for the governance and strategic direction of Willow Wood. The day to day running of the hospice is delegated to the Chief Executive and Senior Management within pre-defined levels of authority. The Chair and Vice Chair work with the Chief Executive and senior management team, and Trustees are on hand to offer their specific skills. 

Board vacancies are identified through a skills audit by the Chair and Board, a role description is formulated and the role is advertised in local media/social media. Newly selected and proposed Trustees are invited to interview and if selected, appointed on a 6-month probationary period.  New Trustees are provided with an induction pack, which includes role description, Hospice Code of Conduct, business plan, Memorandum of Articles, Annual Accounts and published guides on being a Hospice Trustee. Members of the council are expected to achieve 70% attendance in a financial year through either Board or subcommittees. 

In accordance with our general practice, Board meetings are held a minimum of four times a year, the Chief Executive and members of the Senior Management team attend meetings. Individual reports from management, covering all aspects of running the operations, are presented. All Board subcommittee reports are also presented to the meetings. Trustees and Senior Management also set and agree the Hospice Strategic Plan. 

In between Board meetings each trustee is allocated a seat/s at strategic sub-meetings which have specific terms of reference and functions including Finance & Investment, Strategic HR/Volunteer, Health & Safety, Clinical Governance, Clinical Strategy, Workforce Planning, Employee Engagement Forum and Income & Fundraising, all of which encourage collaborative working amongst teams and ensures that all hospice departments are working together as a well-informed unit. Each subgroup is chaired by a trustee who has experience in that field. Working with the Chief Executive, Senior Managers and hospice staff, the purpose of the committee is for the Trustee to report back to Board, make proposals and recommendations which in turn allows the monitoring and progress of objectives. 

Willow Wood is a team-based operation. All personnel at Willow Wood must identify with our values, purpose and vision: to continue to be a leader in hospice care, providing excellence in quality care to the people of Tameside and Glossop. 

Page 14 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **REPORT OF THE TRUSTEES for the Period 1 May 2024 to 31 March 2025** 

## **Risk management** 

The major risks to which the Charity is exposed as identified by the Trustees have been reviewed and strategies have been established to mitigate these risks. This involves identifying the types of risk the Charity faces, prioritising them in terms of potential impact and likelihood of occurrence and identifying means of eliminating or mitigating the risks as appropriate. Risks are under continuous review and evaluation. 

## **STATEMENT OF TRUSTEES' RESPONSIBILITIES** 

The trustees (who are also the directors of Tameside & Glossop Hospice Limited for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). 

Company law requires the trustees to prepare financial statements for each financial year. Under that law, the trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). 

Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to 

- select suitable accounting policies and then apply them consistently; 

- observe the methods and principles in the Charities SORP; 

- make judgements and estimates that are reasonable and prudent; 

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business. 

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 

## **STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS** 

So far as the trustees are aware, there is no relevant information (as defined by Section 418 of the Companies Act 2006) of which the charitable company's auditors are unaware, and each trustee has taken all the steps that they ought to have taken as a trustee in order to make them aware of any audit information and to establish that the charitable company's auditors are aware of that information. 

## **AUDITORS** 

The auditors, Moss & Williamson Limited, will be proposed for re-appointment at the forthcoming Annual General Meeting. 

Report of the trustees, incorporating a strategic report, approved by order of the board of trustees, as the company directors, on 16 December 2025 and signed on the board's behalf by: 

.................................................................... Timothy Jackson - Trustee 

Page 15 



## **REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **Opinion** 

We have audited the financial statements of Tameside & Glossop Hospice Limited (the 'charitable company') for the period ended 31 March 2025 which comprise the Consolidated Statement of Financial Activities, the Consolidated Balance Sheet, the Consolidated Cash Flow Statement and notes to the consolidated financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). 

## In our opinion the financial statements: 

- give a true and fair view of the state of the charitable company's affairs as at 31 March 2025 and of its incoming resources and application of resources, including its income and expenditure, for the period then ended; 

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and 

- have been prepared in accordance with the requirements of the Companies Act 2006. 

## **Basis for opinion** 

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report.  We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.  We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 

## **Conclusions relating to going concern** 

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. 

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report. 

## **Other information** 

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon. 

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. 

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.  We have nothing to report in this regard. 

## **Opinions on other matters prescribed by the Companies Act 2006** 

In our opinion, based on the work undertaken in the course of the audit: 

- the information given in the Report of the Trustees for the financial year for which the financial statements are prepared is consistent with the financial statements; and 

- the Report of the Trustees has been prepared in accordance with applicable legal requirements. 

Page 16 



## **REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **Matters on which we are required to report by exception** 

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees. 

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion: 

- adequate accounting records have not been kept or returns adequate for our audit have not been received 

- from branches not visited by us; or 

- the financial statements are not in agreement with the accounting records and returns; or 

- certain disclosures of trustees' remuneration specified by law are not made; or 

- we have not received all the information and explanations we require for our audit. 

## **Responsibilities of trustees** 

As explained more fully in the Statement of Trustees' Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. 

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so. 

Page 17 



## **REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **Our responsibilities for the audit of the financial statements** 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion.  Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. 

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below: 

We obtained an understanding of the legal and regulatory framework that the company operates in, and the principal risks of non-compliance with laws and regulations which we identified as being significant to the company related to UK Financial Reporting Standards, Company Law, Charity Law, UK Tax Legislation and Health & Safety regulation.  We considered the extent to which the non-compliance with these regulations would have an impact on the accounts. 

The audit procedures we undertook in response to the potential risks relating to irregularities (which include fraud and non-compliance with laws and regulations) included, but not limited to: 

- enquiries of management about procedures for compliance with laws and regulations 

- enquiring of management as to whether they had any knowledge of actual, suspected or alleged fraud 

- we inspected the minutes of meetings of those charges with governance 

- in addressing the risk of fraud through management override of controls we tested the appropriateness of journals entries 

- we ensured the audit team were alert for any identification of non-compliance throughout the audit 

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation.  This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance.  The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation. 

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors. 

## **Use of our report** 

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed. 

David Evans FCA (Senior Statutory Auditor) for and on behalf of Moss & Williamson Limited Chartered Accountants Statutory Auditor Booth Street Chambers Ashton-under-Lyne Lancashire OL6 7LQ 

16 December 2025 

Page 18 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING AN INCOME AND EXPENDITURE ACCOUNT) for the Period 1 May 2024 to 31 March 2025** 

|Unrestricted<br>funds<br>Notes<br>£<br>**INCOME AND ENDOWMENTS FROM**<br>Donations and legacies<br>2<br>**1,634,955**<br>Other trading activities<br>3<br>**1,597,033**<br>Investment income<br>4<br>**125,510**<br>Other income<br>**85,277**<br>**Total**<br>**3,442,775**<br>**EXPENDITURE ON**<br>**Raising funds**<br>Raising donations and legacies<br>5<br>**305,159**<br>**305,159**<br>**Charitable activities**<br>6<br>Hospice<br>**2,917,305**<br>Fundraising<br>**58,745**<br>Governance<br>**41,454**<br>Lottery<br>**148,087**<br>Trading expenses of subsidiary<br>**834,461**<br>**4,000,052**<br>**Total**<br>**4,305,211**<br>Net gains on investments<br>**37,270**<br>**NET INCOME/(EXPENDITURE)**<br>**(825,166)**<br>**RECONCILIATION OF FUNDS**<br>Total funds brought forward<br>**6,505,974**<br>**TOTAL FUNDS CARRIED FORWARD**<br>**5,680,808**|Restricted<br>fund<br>£<br>**139,724**<br>**-**<br>**-**<br>**-**<br>**139,724**<br>**-**<br>**-**<br>**92,040**<br>**-**<br>**-**<br>**-**<br>**-**<br>**92,040**<br>**92,040**<br>**-**<br>**47,684**<br>**175,292**<br>**222,976**|**Period**<br>**1.5.24**<br>**to**<br>Year ended<br>**31.3.25**<br>30.4.24<br>**Total**<br>Total<br>**funds**<br>funds<br>**£**<br>£<br>**1,774,679**<br>2,783,599<br>**1,597,033**<br>1,707,129<br>**125,510**<br>192,256<br>**85,277**<br>92,221<br>**3,582,499**<br>4,775,205<br>**305,159**<br>253,549<br>**305,159**<br>253,549<br>**3,009,345**<br>3,173,368<br>**58,745**<br>50,078<br>**41,454**<br>38,331<br>**148,087**<br>162,794<br>**834,461**<br>824,169<br>**4,092,092**<br>4,248,740<br>**4,397,251 **<br>4,502,289<br>**37,270**<br>65,990<br>**(777,482)**<br>338,906<br>**6,681,266**<br>6,342,360<br>**5,903,784 **<br>6,681,266|
|---|---|---|



The notes form part of these financial statements 

Page 19 



## **TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **CONSOLIDATED BALANCE SHEET 31 March 2025** 

|Notes<br>**FIXED ASSETS**<br>Tangible assets<br>13<br>**Investments**<br>Investments<br>14<br>Investment property<br>15<br>**CURRENT ASSETS**<br>Stocks<br>16<br>Debtors<br>17<br>Cash at bank and in hand<br>**CREDITORS**<br>Amounts falling due within one year<br>18<br>**NET CURRENT ASSETS**<br>**TOTAL ASSETS LESS CURRENT**<br>**LIABILITIES**<br>**NET ASSETS**<br>**FUNDS**<br>21<br>Unrestricted funds:<br>General fund<br>Designated<br>Restricted funds:<br>Restricted<br>**TOTAL FUNDS**|Unrestricted<br>funds<br>£<br>**2,375,945**<br>**2,551,337**<br>**215,000**<br>**5,142,282**<br>**15,754**<br>**704,629**<br>**315,692 **<br>**1,036,075**<br>**(497,549)**<br>**538,526**<br>**5,680,808**<br>**5,680,808**|Restricted<br>fund<br>£<br>**38,061**<br>**184,915**<br>**-**<br>**222,976**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**222,976**<br>**222,976**|**2025**<br>**Total**<br>**funds**<br>**£**<br>**2,414,006**<br>**2,736,252**<br>**215,000**<br>**5,365,258**<br>**15,754**<br>**704,629**<br>**315,692 **<br>**1,036,075**<br>**(497,549)**<br>**538,526**<br>**5,903,784**<br>**5,903,784 **<br>**3,304,995**<br>**2,375,813**<br>**5,680,808**<br>**222,976**<br>**5,903,784 **|2024<br>Total<br>funds<br>£<br>2,401,043<br>2,927,755<br>215,000<br>5,543,798<br>7,746<br>912,325<br>642,720<br>1,562,791<br>(425,323)<br>1,137,468<br>6,681,266<br>6,681,266<br>4,092,157<br>2,413,817<br>6,505,974<br>175,292<br>6,681,266|
|---|---|---|---|---|



The financial statements were approved by the Board of Trustees and authorised for issue on 16 December 2025 and were signed on its behalf by: 

............................................. Timothy Jackson - Trustee 

The notes form part of these financial statements 

Page 20 

continued... 



## **TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **COMPANY BALANCE SHEET 31 March 2025** 

|Notes<br>**FIXED ASSETS**<br>Tangible assets<br>13<br>**Investments**<br>Investments<br>14<br>Investment property<br>15<br>**CURRENT ASSETS**<br>Stocks<br>16<br>Debtors<br>17<br>Cash at bank and in hand<br>**CREDITORS**<br>Amounts falling due within one year<br>18<br>**NET CURRENT ASSETS**<br>**TOTAL ASSETS LESS CURRENT**<br>**LIABILITIES**<br>**NET ASSETS**<br>**FUNDS**<br>21<br>Unrestricted funds:<br>General fund<br>Designated<br>Restricted funds:<br>Restricted<br>**TOTAL FUNDS**|Unrestricted<br>funds<br>£<br>**2,322,937**<br>**2,551,347**<br>**215,000**<br>**5,089,284**<br>**15,754**<br>**958,391**<br>**18,182 **<br>**992,327**<br>**(401,378)**<br>**590,949**<br>**5,680,233**<br>**5,680,233**|Restricted<br>fund<br>£<br>**38,061**<br>**184,915**<br>**-**<br>**222,976**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**222,976**<br>**222,976**|**2025**<br>**Total**<br>**funds**<br>**£**<br>**2,360,998**<br>**2,736,262**<br>**215,000**<br>**5,312,260**<br>**15,754**<br>**958,391**<br>**18,182 **<br>**992,327**<br>**(401,378)**<br>**590,949**<br>**5,903,209**<br>**5,903,209**<br>**3,304,420**<br>**2,375,813**<br>**5,680,233**<br>**222,976**<br>**5,903,209**|2024<br>Total<br>funds<br>£<br>2,359,880<br>2,927,765<br>215,000<br>5,502,645<br>7,746<br>1,430,464<br>38,459<br>1,476,669<br>(298,624)<br>1,178,045<br>6,680,690<br>6,680,690<br>4,091,581<br>2,413,817<br>6,505,398<br>175,292<br>6,680,690|
|---|---|---|---|---|



The financial statements were approved by the Board of Trustees and authorised for issue on 16 December 2025 and were signed on its behalf by: 

The notes form part of these financial statements 

............................................. Timothy Jackson - Trustee 

Page 21 



## **TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **CONSOLIDATED CASH FLOW STATEMENT for the Period 1 May 2024 to 31 March 2025** 

|Notes<br>**Cash flows from operating activities**<br>Cash generated from operations<br>1<br>Net cash used in operating activities<br>**Cash flows from investing activities**<br>Purchase of tangible fixed assets<br>Purchase of fixed asset investments<br>Sale of tangible fixed assets<br>Sale of fixed asset investments<br>Dividends received<br>Net cash provided by investing activities<br>**Change in cash and cash equivalents**<br>**in the reporting period**<br>**Cash and cash equivalents at the**<br>**beginning of the reporting period**<br>**Cash and cash equivalents at the end**<br>**of the reporting period**|**Period**<br>**1.5.24**<br>**to**<br>Year ended<br>**31.3.25**<br>30.4.24<br>**£**<br>£<br>**(486,109) **<br>(182,520)<br>**(486,109) **<br>(182,520)<br>**(108,345)**<br>(36,001)<br>**(314,034)**<br>(408,397)<br>**-**<br>171,758<br>**542,540**<br>374,450<br>**38,920**<br>87,784<br>**159,081 **<br>189,594<br>**(327,028)**<br>7,074<br>**642,720**<br>635,646<br>**315,692 **<br>642,720|
|---|---|



The notes form part of these financial statements 

Page 22 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **NOTES TO THE CONSOLIDATED CASH FLOW STATEMENT for the Period 1 May 2024 to 31 March 2025** 

## **1. RECONCILIATION OF NET (EXPENDITURE)/INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES** 

|**Net (expenditure)/income for the reporting period (as per the**<br>**Statement of Financial Activities)**<br>**Adjustments for:**<br>Depreciation charges<br>Gain on investments<br>Profit on disposal of fixed assets<br>Dividends received<br>(Increase)/decrease in stocks<br>Decrease/(increase) in debtors<br>Increase in creditors<br>**Net cash used in operations**<br>**ANALYSIS OF CHANGES IN NET FUNDS**<br>At 1.5.24<br>£<br>**Net cash**<br>Cash at bank and in hand<br>**642,720**<br>**642,720**<br>**Total**<br>**642,720**|**Period**<br>**1.5.24**<br>**to**<br>Year ended<br>**31.3.25**<br>30.4.24<br>**£**<br>£<br>**(777,482)**<br>338,906<br>**95,394**<br>98,510<br>**(37,270)**<br>(65,990)<br>**-**<br>(41,922)<br>**(38,920)**<br>(87,784)<br>**(8,008)**<br>3,772<br>**207,951**<br>(430,366)<br>**72,226**<br>2,354<br>**(486,109) **<br>(182,520)<br>Cash flow<br>**At 31.3.25**<br>**£**<br>**£**<br>**(327,028)**<br>**315,692 **<br>**(327,028)**<br>**315,692 **<br>**(327,028)**<br>**315,692 **|
|---|---|



## **2. ANALYSIS OF CHANGES IN NET FUNDS** 

The notes form part of these financial statements 

Page 23 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS for the Period 1 May 2024 to 31 March 2025** 

## **1. ACCOUNTING POLICIES** 

## **Basis of preparing the financial statements** 

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets. 

The presentation currency of the financial statements is the pound Sterling (£). 

## **Preparation of consolidated financial statements** 

As permitted by Section 408 of the Companies Act 2006, the Statement of Financial Activity of the parent Charity is not presented as part of the financial statements. 

## **Income** 

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably. 

## **Expenditure** 

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources. 

## **Allocation and apportionment of costs** 

Fund-raising costs are those incurred in seeking voluntary contributions including marketing and advertising but do not include the costs of disseminating information in support of charitable activities. 

Governance costs are those incurred in connection with governance of the charity and are associated with constitutional and statutory requirements and strategic non-day-to-day management of the charity's activities. 

## **Tangible fixed assets** 

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life. 

Freehold property -  2% on cost Long leasehold -  2% on cost Plant and machinery -  20% on cost Computer equipment -  33% on cost 

## **Investment property** 

Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in the Statement of Financial Activities. 

## **Stocks** 

Bought in stocks are valued at the lower of cost or net realisable value after making due allowance for obsolete or slow-moving items.  Unsold donated items are not included in closing stock because of the uncertainty and impracticality of valuation. 

Page 24 

continued... 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued for the Period 1 May 2024 to 31 March 2025** 

## **1. ACCOUNTING POLICIES - continued** 

## **Taxation** 

The charity is exempt from corporation tax on its charitable activities. 

## **Fund accounting** 

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees. 

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes. 

Designated Funds are unrestricted funds with the specific purpose of funding the building and development of Willow Wood Hospice and includes £100,000 as a Support Grant (enhanced by interest generated on the funds specifically invested for these purposes) and £497,000 as an Asset Replacement Provision. In addition, several years ago the Hospice received two grants from the PCT totalling £936,118 which the Trustees allocated for the building extension and extensive Hospice refurbishment programme that was undertaken. The net balance of these grants continue to be held by the Trustees against future refurbishment costs and continue to be enhanced by interest generated on funds invested for this purpose. Two further grants of £60,000 were received during 2012 from the PCT and the Trustees have designated these for future Hospice development. Again, these are enhanced by interest generated on the funds invested for this purpose. At the balance sheet date, the Designated Funds invested for future Hospice development stands at £960,086 (2024: £970,974). The remainder of the Designated funds have already been spent by the Trustees and are within the Accounts as Long Leasehold Property £1,395,198 (2024 - £1,442,842). 

## **Voluntary help and gifts in kind** 

No value has been placed on the help received by Tameside & Glossop Hospice Limited during the year. The charity receives a number of non-cash donations, it is not practicable for these gifts in kind to be recognised and valued when received. Income is accounted for in the accounting period in which the gift is sold. There were no individual gifts of significant value. 

## **2. DONATIONS AND LEGACIES** 

|Grants<br>Individuals<br>Companies<br>99ers Club<br>Trusts<br>In Memoriam<br>Gift aid shop sales<br>Gift Aid/G.A.Y.E.<br>Collecting cans<br>Deed of covenant<br>Legacies<br>Death certificates<br>Members' subscriptions<br>Carried forward|**Period**<br>**1.5.24**<br>**to**<br>Year ended<br>**31.3.25**<br>30.4.24<br>**£**<br>£<br>**840,671**<br>789,945<br>**101,018**<br>62,109<br>**47,522**<br>24,156<br>**2,100**<br>2,100<br>**57,155**<br>50,792<br>**185,520**<br>158,644<br>**191,134**<br>201,452<br>**86,618**<br>96,412<br>**24,233**<br>22,751<br>**11,182**<br>6,945<br>**223,316**<br>1,356,477<br>**3,690**<br>11,316<br>**520**<br>500<br>**1,774,679**<br>2,783,599|
|---|---|



Page 25 

continued... 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued for the Period 1 May 2024 to 31 March 2025** 

## **2. DONATIONS AND LEGACIES - continued** 

|Brought forward<br>Grants received, included in the above, are as follows:<br>Other grants<br>**3.**<br>**OTHER TRADING ACTIVITIES**<br>Shop income<br>Lottery income<br>Superdraw income<br>External Fundraising<br>Internal Fundraising<br>Sale of promotional items<br>Calendars & Christmas cards<br>Seasonal promotions<br>Appeal income<br>Coffee mornings<br>Light up a Life<br>Hospice ball<br>Sahara Trek<br>Butterfly Release<br>Fashion shows<br>Golf day<br>Bunny hop<br>Memory stone<br>Direct mail campaign<br>Strictly Come Dancing<br>Zip wire<br>The big give<br>Ultra challenge<br>Carried forward|**Period**<br>**1.5.24**<br>**to**<br>Year ended<br>**31.3.25**<br>30.4.24<br>**£**<br>£<br>**1,774,679**<br>2,783,599<br>**1,774,679**<br>2,783,599<br>**Period**<br>**1.5.24**<br>**to**<br>Year ended<br>**31.3.25**<br>30.4.24<br>**£**<br>£<br>**840,671**<br>789,945<br>**Period**<br>**1.5.24**<br>**to**<br>Year ended<br>**31.3.25**<br>30.4.24<br>**£**<br>£<br>**863,591**<br>889,680<br>**418,153**<br>482,331<br>**47,767**<br>63,274<br>**101,742**<br>78,413<br>**21,602**<br>22,651<br>**8,391**<br>2,591<br>**(3,267)**<br>(3,496)<br>**-**<br>(475)<br>**-**<br>1,611<br>**8,924**<br>8,598<br>**14,736**<br>13,364<br>**15,708**<br>17,681<br>**-**<br>3,543<br>**10,739**<br>4,573<br>**6,060**<br>5,902<br>**6,865**<br>6,696<br>**32,983**<br>40,388<br>**4,660**<br>4,201<br>**9,974**<br>14,384<br>**13,548**<br>(483)<br>**10**<br>13,454<br>**-**<br>32,573<br>**-**<br>1,095<br>**1,582,186**<br>1,702,549|
|---|---|



Page 26 

continued... 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued for the Period 1 May 2024 to 31 March 2025** 

## **3. OTHER TRADING ACTIVITIES - continued** 

|Brought forward<br>Christmas tree recycling<br>Wonderful ladies lunch<br>Enterprise challenge<br>Foam fest<br>**4.**<br>**INVESTMENT INCOME**<br>Rent received<br>Interest on Investments<br>Dividends received<br>Profit-disposal of investments<br>**5.**<br>**RAISING DONATIONS AND LEGACIES**<br>Staff costs<br>Fundraising costs|**Period**<br>**1.5.24**<br>**to**<br>Year ended<br>**31.3.25**<br>30.4.24<br>**£**<br>£<br>**1,582,186**<br>1,702,549<br>**4,583**<br>5,130<br>**-**<br>(550)<br>**10,931**<br>-<br>**(667)**<br>-<br>**1,597,033**<br>1,707,129<br>**Period**<br>**1.5.24**<br>**to**<br>Year ended<br>**31.3.25**<br>30.4.24<br>**£**<br>£<br>**79,562**<br>95,585<br>**7,028**<br>8,887<br>**45,452**<br>48,711<br>**(6,532)**<br>39,073<br>**125,510**<br>192,256<br>**Period**<br>**1.5.24**<br>**to**<br>Year ended<br>**31.3.25**<br>30.4.24<br>**£**<br>£<br>**285,517**<br>221,044<br>**19,642**<br>32,505<br>**305,159**<br>253,549|
|---|---|
|||



Page 27 

continued... 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued for the Period 1 May 2024 to 31 March 2025** 

## **6. CHARITABLE ACTIVITIES COSTS** 

|Hospice<br>Fundraising<br>Governance<br>Lottery<br>Trading expenses of subsidiary<br>**7.**<br>**DIRECT COSTS OF CHARITABLE ACTIVITIES**|Direct<br>Costs (see<br>note 7)<br>£<br>**2,378,882**<br>**3,208**<br>**-**<br>**148,087**<br>**834,461 **<br>**3,364,638**|Support<br>costs (see<br>note 8)<br>£<br>**630,463**<br>**55,537**<br>**41,454**<br>**-**<br>**-**<br>**727,454 **|Totals<br>£<br>**3,009,345**<br>**58,745**<br>**41,454**<br>**148,087**<br>**834,461 **<br>**4,092,092 **|
|---|---|---|---|



|Staff costs<br>Therapy costs & consumables<br>Support costs<br>Stationery<br>Catering supplies<br>Medical supplies<br>Training expenses<br>Laundry & cleaning<br>Waste disposal<br>Depreciation<br>Repairs & maintenance<br>Rental property expenditure<br>Sundry equipment<br>Website costs<br>Travel & minibus<br>Recruitment<br>Trading expenses of subsidiary<br>Lottery prizes<br>Superdraw prizes<br>Lottery administration costs|**Period**<br>**1.5.24**<br>**to**<br>Year ended<br>**31.3.25**<br>30.4.24<br>**£**<br>£<br>**2,007,241**<br>2,157,135<br>**4,367**<br>1,943<br>**96,552**<br>96,043<br>**12,929**<br>8,797<br>**47,013**<br>49,816<br>**28,477**<br>31,881<br>**9,143**<br>10,160<br>**11,690**<br>17,492<br>**7,909**<br>8,135<br>**80,562**<br>85,856<br>**45,764**<br>142,641<br>**11,305**<br>7,638<br>**2,861**<br>1,165<br>**6,726**<br>2,891<br>**7,495**<br>9,571<br>**2,056**<br>12,327<br>**834,461**<br>824,169<br>**69,571**<br>75,475<br>**5,760**<br>6,000<br>**72,756**<br>81,319<br>**3,364,638**<br>3,630,454|
|---|---|



Page 28 

continued... 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued for the Period 1 May 2024 to 31 March 2025** 

## **8. SUPPORT COSTS** 

|Management<br>£<br>Hospice<br>**627,229**<br>Fundraising<br>**49,596**<br>Governance<br>**-**<br>**676,825**|Governance<br>Finance<br>costs<br>£<br>£<br>**3,234**<br>**-**<br>**5,941**<br>**-**<br>**-**<br>**41,454 **<br>**9,175**<br>**41,454 **|Totals<br>£<br>**630,463**<br>**55,537**<br>**41,454 **<br>**727,454**|
|---|---|---|



Support costs, included in the above, are as follows: 

## **Management** 

|Salaries, NI & pensions<br>Rates and water<br>Insurance<br>Heat & light<br>Communications<br>Postage<br>Computer support costs<br>Sundry expenses<br>Subscription/registration fees<br>Portfolio management fees<br>Depreciation of tangible and heritage<br>assets<br>**Finance**<br>Bank charges|Hospice<br>Fundraising<br>£<br>£<br>**369,070**<br>**27,779**<br>**6,372**<br>**480**<br>**31,284**<br>**2,355**<br>**105,663**<br>**7,953**<br>**9,463**<br>**712**<br>**6,331**<br>**1,962**<br>**55,428**<br>**4,406**<br>**13,096**<br>**1,021**<br>**4,674**<br>**982**<br>**17,945**<br>**1,351**<br>**7,903**<br>**595**<br>**627,229**<br>**49,596**<br>Hospice<br>Fundraising<br>£<br>£<br>**3,234 **<br>**5,941**|**Period**<br>**1.5.24**<br>**to**<br>Year ended<br>**31.3.25**<br>30.4.24<br>Total<br>Total<br>activities<br>activities<br>£<br>£<br>**396,849**<br>**345,575**<br>**6,852**<br>**10,196**<br>**33,639**<br>**32,632**<br>**113,616**<br>**64,471**<br>**10,175**<br>**8,597**<br>**8,293**<br>**5,464**<br>**59,834**<br>**61,541**<br>**14,117**<br>**11,415**<br>**5,656**<br>**4,697**<br>**19,296**<br>**16,519**<br>**8,498**<br>**8,076**<br>**676,825**<br>**569,183**<br>**Period**<br>**1.5.24**<br>**to**<br>Year ended<br>**31.3.25**<br>30.4.24<br>Total<br>Total<br>activities<br>activities<br>£<br>£<br>**9,175**<br>**10,772**|
|---|---|---|



Page 29 

continued... 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued for the Period 1 May 2024 to 31 March 2025** 

## **8. SUPPORT COSTS - continued Governance costs** 

|**SUPPORT COSTS - continued**<br>**Governance costs**|||
|---|---|---|
||**Period**||
||**1.5.24**||
||**to**|Year ended|
||**31.3.25**|30.4.24|
|||Total|
||Governance|activities|
||£|£|
|Auditors' remuneration|**10,575**|**10,800**|
|Legal & professional fees|**30,879**|**27,531 **|
||**41,454 **|**38,331**|



## **9. NET INCOME/(EXPENDITURE)** 

Net income/(expenditure) is stated after charging/(crediting): 

|Auditors' remuneration<br>Depreciation - owned assets<br>Surplus on disposal of fixed assets|**Period**<br>**1.5.24**<br>**to**<br>Year ended<br>**31.3.25**<br>30.4.24<br>**£**<br>£<br>**10,575**<br>10,800<br>**95,382**<br>98,509<br>**-**<br>(41,922)|
|---|---|



## **10. TRUSTEES' REMUNERATION AND BENEFITS** 

There were no trustees' remuneration or other benefits for the period ended 31 March 2025 nor for the year ended 30 April 2024. 

## **Trustees' expenses** 

There were no  trustees' expenses paid for the period ended 31 March 2025 nor for the year ended 30 April 2024. 

## **11. STAFF COSTS** 

|Wages and salaries<br>Social Security costs<br>Pension costs|**Period**<br>**1.5.24**<br>**to**<br>Year ended<br>**31.03.25**<br>30.4.24<br>**£**<br>£<br>**2,790,177**<br>2,728,723<br>**257,019**<br>248,964<br>**207,759**<br>194,930<br>**3,254,955**<br>3,172,617|
|---|---|



Page 30 

continued... 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued for the Period 1 May 2024 to 31 March 2025** 

## **11. STAFF COSTS - continued** 

The average monthly number of employees during the period was as follows: 

|Employees|**Period**<br>**1.5.24**<br>**to**<br>Year ended<br>**31.3.25**<br>30.4.24<br>**111**<br>100|
|---|---|



The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was: 

|£60,000|was:|||
|---|---|---|---|
|||**Period**||
|||**1.5.24**||
|||**to**|Year ended|
|||**31.3.25**|30.4.24|
|£70,001|- £80,000|**1**|1|
|£80,001|- £90,000|**-**|1|
|£90,001|- £100,000|**1**|-|
|||**2**|2|



Page 31 

continued... 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued for the Period 1 May 2024 to 31 March 2025** 

## **12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES** 

|Unrestricted<br>funds<br>£<br>**INCOME AND ENDOWMENTS FROM**<br>Donations and legacies<br>2,671,471<br>Other trading activities<br>1,707,129<br>Investment income<br>192,256<br>Other income<br>92,221<br>**Total**<br>4,663,077<br>**EXPENDITURE ON**<br>**Raising funds**<br>Raising donations and legacies<br>253,549<br>253,549<br>**Charitable activities**<br>Hospice<br>3,047,815<br>Fundraising<br>50,078<br>Governance<br>40,951<br>Lottery<br>162,794<br>Trading expenses<br>820,789<br>**Total**<br>4,375,976<br>Net gains on investments<br>65,990<br>**NET INCOME/(EXPENDITURE)**<br>353,091<br>**RECONCILAITION OF FUNDS**<br>Total funds brought forward<br>6,152,883<br>**TOTAL FUNDS CARRIED FORWARD**<br>6,505,974|Restricted<br>fund<br>£<br>112,128<br>-<br>-<br>-<br>112,128<br>-<br>-<br>126,313<br>-<br>-<br>-<br>-<br>126,313<br>-<br>(14,185)<br>189,477<br>175,292|Total<br>funds<br>£<br>2,783,599<br>1,707,129<br>192,256<br>92,221<br>4,775,205<br>253,549<br>253,549<br>3,174,128<br>50,078<br>40,951<br>162,794<br>820,789<br>4,502,289<br>65,990<br>338,906<br>6,342,360<br>6,681,266|
|---|---|---|



Page 32 

continued... 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – continued for the Period 1 May 2024 to 31 March 2025** 

## **13. TANGIBLE FIXED ASSETS** 

## **GROUP** 

|**COST**<br>At 1 May 2024<br>Additions<br>At 31 March 2025<br>**DEPRECIATION**<br>At 1 May 2024<br>Charge for year<br>At 31 March 2025<br>**NET BOOK VALUE**<br>At 31 March 2025<br>At 30 April 2024<br>**COST**<br>At 1 May 2024<br>Additions<br>At 31 March 2025<br>**DEPRECIATION**<br>At 1 May 2024<br>Charge for year<br>At 31 March 2025<br>**NET BOOK VALUE**<br>At 31 March 2025<br>At 30 April 2024|Freehold<br>property<br>£<br>**503,280**<br>**-**<br>**503,280**<br>**123,269**<br>**9,227**<br>**132,496**<br>**370,784 **<br>380,011<br>Plant and<br>machinery<br>£<br>**422,754**<br>**80,920**<br>**503,674**<br>**381,935**<br>**14,115**<br>**396,050**<br>**107,624**<br>40,819|Long Improvements<br>leasehold<br>to property<br>£<br>£<br>**3,134,294**<br>**48,159**<br>**-**<br>**18,166**<br>**3,134,294 **<br>**66,325**<br>**1,210,361**<br>**7,391**<br>**57,462 **<br>**6,080**<br>**1,267,823**<br>**13,471**<br>**1,866,471**<br>**52,854 **<br>1,923,933<br>40,768<br>Computer<br>equipment<br>Totals<br>£<br>£<br>**93,014**<br>**4,201,501**<br>**9,259**<br>**108,345**<br>**102,273**<br>**4,309,846**<br>**77,502**<br>**1,800,458**<br>**8,498**<br>**95,382 **<br>**86,000**<br>**1,895,840**<br>**16,273**<br>**2,414,006**<br>15,512<br>2,401,043|
|---|---|---|



Page 33 

continued... 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued for the Period 1 May 2024 to 31 March 2025** 

## **13. TANGIBLE FIXED ASSETS - continued** 

## **COMPANY** 

|**COST**<br>At 1 May 2024<br>Additions<br>At 31 March 2025<br>**DEPRECIATION**<br>At 1 May 2024<br>Charge for year<br>At 31 March 2025<br>**NET BOOK VALUE**<br>At 31 March 2025<br>At 30 April 2024<br>**COST**<br>At 1 May 2024<br>Additions<br>At 31 March 2025<br>**DEPRECIATION**<br>At 1 May 2024<br>Charge for year<br>At 31 March 2025<br>**NET BOOK VALUE**<br>At 31 March 2025<br>At 30 April 2024|Freehold<br>property<br>£<br>**503,280**<br>**-**<br>**508,280**<br>**123,269**<br>**9,227**<br>**132,496**<br>**370,784 **<br>380,011|Long<br>leasehold<br>£<br>**3,134,294**<br>**-**<br>**3,134,294 **<br>**1,210,361**<br>**57,462 **<br>**1,267,823**<br>**1,866,471**<br>1,923,933<br>Computer<br>equipment<br>£<br>**93,014**<br>**9,259**<br>**102,273**<br>**77,502**<br>**8,498**<br>**86,000**<br>**16,273**<br>15,512|Plant and<br>machinery<br>£<br>**405,338**<br>**80,920**<br>**486,258**<br>**364,914**<br>**13,874**<br>**378,788**<br>**107,470**<br>40,424<br>Totals<br>£<br>**4,135,926**<br>**90,179**<br>**4,226,105**<br>**1,776,046**<br>**89,061 **<br>**1,865,107 **<br>**2,360,998**<br>2,359,880|
|---|---|---|---|



Page 34 

continued... 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued for the Period 1 May 2024 to 31 March 2025** 

## **14. FIXED ASSET INVESTMENTS** 

## **GROUP** 

|Listed<br>investments<br>£<br>**MARKET VALUE**<br>At 1 May 2024<br>**1,982,339**<br>Additions<br>**314,034**<br>Disposals<br>**(346,339)**<br>Unrealised gain<br>**37,003**<br>At 31 March 2025<br>**1,987,037 **<br>**NET BOOK VALUE**<br>At 31 March 2025<br>**1,987,037 **<br>At 30 April 2024<br>1,982,339<br>**COMPANY**<br>Shares in<br> <br>group<br>Listed<br>undertakings investments<br>£<br>£<br>**MARKET VALUE**<br>At 1 May 2023<br>**10**<br>**1,982,339**<br>Additions<br>**-**<br>**314,034**<br>Disposals<br>**-**<br>**(346,339)**<br>Revaluations<br>**-**<br>**37,003**<br>At 30 April 2024<br>**10**<br>**1,987,037 **<br>**NET BOOK VALUE**<br>At 30 April 2024<br>**10**<br>**1,987,037 **<br>At 30 April 2023<br>10<br>1,982,339|Notice &<br>Term bank<br>accounts<br>£<br>**945,416**<br>**-**<br>**(196,201)**<br>**-**<br>**749,215**<br>**749,215**<br>945,416<br>Notice &<br>Term bank<br>accounts<br>£<br>**945,416**<br>**-**<br>**(196,201)**<br>**-**<br>**749,215**<br>**749,215**<br>945,416|Totals<br>£<br>**2,927,755**<br>**314,034**<br>**(542,540)**<br>**37,003**<br>**2,736,252 **<br>**2,736,252 **<br>2,927,755<br>Totals<br>£<br>**2,927,765**<br>**314,034**<br>**(542,540)**<br>**37,003**<br>**2,736,262 **<br>**2,736,262 **<br>2,927,755|
|---|---|---|



There were no investment assets outside the UK. Listed investments are reported at market value as at 31 March 2025.. 

Cost or valuation at 31 March 2025 is represented by: 

|Listed<br>investments<br>**£**<br>Valuation in 2025<br>**1,987,037**<br>Cost<br>**-**<br>**1,987,037 **|Notice &<br>Term bank<br>accounts<br>**£**<br>**-**<br>**749,215**<br>**749,215**|Totals<br>**£**<br>**1,987,037**<br>**749,215**<br>**2,736,252 **|
|---|---|---|



Page 35 

continued... 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued for the Period 1 May 2024 to 31 March 2025** 

## **14. FIXED ASSET INVESTMENTS - continued** 

The company's investments at the balance sheet date in the share capital of companies include the following: 

## **Willow Wood Hospice Promotions Limited** 

Registered office: Willow Wood Hospice, Willow Wood Close, Ashton-under-Lyne, OL6 6SL Nature of business: Charity shops and lottery. 

|%<br>Class of share:<br>holding<br>Ordinary<br>**100**<br>**2025**<br>**£**<br>Aggregate capital and reserves<br>**586**<br>**15.**<br>**INVESTMENT PROPERTY**<br>**FAIR VALUE**<br>At 1 May 2024<br>and 31 March 2025<br>**NET BOOK VALUE**<br>At 31 March 2025<br>At 30 April 2024|2024<br>£<br>586<br>**£**<br>**215,000**|
|---|---|
||**215,000**|
||215,000|



The Investment Properties were acquired as part of two legacies that were left to the Hospice. The properties are residential properties and were valued by an independent valuer when the estates of the legacies were being valued. 

The Trustees made the decision to let the properties out to generate on going funds for the Hospice. 

## **16. STOCKS** 

|Stocks|**2025**<br>**£**<br>**15,754 **|2024<br>£<br>7,746|
|---|---|---|



Stocks consist of items acquired for medical and fundraising purposes. 

## **17. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR** 

## **GROUP** 

|Debtors & prepayments<br>Amounts owed by group undertakings<br>Other debtors<br>VAT|**2025**<br>**£**<br>**109,348**<br>**255**<br>**546,149**<br>**48,877**<br>**704,629**|2024<br>£<br>262,591<br>-<br>609,857<br>39,877|
|---|---|---|
|||912,325|



Page 36 

continued... 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued for the Period 1 May 2024 to 31 March 2025** 

## **17. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR - continued** 

## **COMPANY** 

|Debtors & prepayments<br>Amounts owed by group undertakings<br>Other debtors<br>VAT|**2025**<br>**£**<br>**109,348**<br>**312,557**<br>**493,11**<br>**43,370**<br>**958,391 **|2024<br>£<br>262,591<br>557,611<br>609,857<br>39,877<br>1,430,464|
|---|---|---|



## **18. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR** 

## **GROUP** 

|Trade creditors<br>Social security and other taxes<br>Other creditors<br>Grants received in advance<br>Accruals & deferred income<br>**COMPANY**<br>Bank loans and overdrafts (see note 19)<br>Trade creditors<br>Social security and other taxes<br>Other creditors<br>Grants received in advance<br>Accruals & deferred income<br>**19.**<br>**LOANS**<br>An analysis of the maturity of loans is given below:<br>Amounts falling due within one year on demand:<br>Bank overdrafts|**2025**<br>**£**<br>**146,060**<br>**161,435**<br>**119,114**<br>**16,920**<br>**54,020**<br>**497,549**<br>**2025**<br>**£**<br>**56,166**<br>**110,230**<br>**161,435**<br>**2,607**<br>**16,920**<br>**54,020**<br>**401,378**<br>**2025**<br>**£**<br>**56,166**|2024<br>£<br>63,485<br>99,492<br>94,239<br>123,800<br>44,307<br>425,323<br>2024<br>£<br>-<br>29,975<br>99,492<br>1,050<br>123,800<br>44,307<br>298,624<br>2024<br>£<br>-|
|---|---|---|



Page 37 

continued... 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued for the Period 1 May 2024 to 31 March 2025** 

## **20. LEASING AGREEMENTS** 

Minimum lease payments under non-cancellable operating leases fall due as follows: 

|**GROUP**<br>Within one year<br>Between one and five years<br>In more than five years<br>**COMPANY**<br>Within one year<br>Between one and five years|**2025**<br>**£**<br>**62,574**<br>**176,193**<br>**141,667 **<br>**380,434 **<br>**2025**<br>**£**<br>**8,095**<br>**15,360**<br>**23,455**|2024<br>£<br>63,033<br>205,807<br>165,833<br>434,673<br>2024<br>£<br>8,283<br>22,765 <br>31,048|
|---|---|---|



## **21. MOVEMENT IN FUNDS GROUP** 

|**Unrestricted funds**<br>General fund<br>Designated<br>**Restricted funds**<br>Restricted<br>**TOTAL FUNDS**|At 1.5.24<br>£<br>**4,092,157**<br>**2,413,817**<br>**6,505,974**<br>**175,292**<br>**6,681,266**|Net<br>movement<br>in funds<br>£<br>**(782,162)**<br>**(43,004)**<br>**(825,166)**<br>**47,684**<br>**(777,482)**|Transfers<br>between<br>funds<br>£<br>**(5,000)**<br>**5,000**<br>**-**<br>**-**<br>**-**|At 31.3.25<br>£<br>**3,304,995**<br>**2,375,813**<br>**5,680,808**<br>**222,976**<br>**5,903,784**|
|---|---|---|---|---|



Page 38 

continued... 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued for the Period 1 May 2024 to 31 March 2025** 

## **21. MOVEMENT IN FUNDS - continued** 

Net movement in funds, included in the above are as follows: 

|**Unrestricted funds**<br>General fund<br>Designated<br>**Restricted funds**<br>Restricted<br>**TOTAL FUNDS**|Incoming<br>resources<br>£<br>**3,438,135**<br>**4,640**<br>**3,442,775**<br>**139,724**<br>**3,582,499**|Resources<br>expended<br>£<br>**(4,257,567)**<br>**(47,644)**<br>**(4,305,211)**<br>**(92,040)**<br>**(4,397,251)**|Gains and<br>losses<br>£<br>**37,270**<br>**-**<br>**37,270**<br>**-**<br>**37,270**|Movement<br>in funds<br>£<br>**(782,162)**<br>**(43,004)**<br>**(825,166)**<br>**47,684**<br>**(777,482)**|
|---|---|---|---|---|



## **Comparatives for movement in funds** 

|**Unrestricted funds**<br>General fund<br>Designated<br>**Restricted funds**<br>Restricted<br>**TOTAL FUNDS**|At 1.5.23<br>£<br>3,696,684<br>2,456,199<br>6,152,883<br>189,477<br>6,342,360|Net<br>movement<br>in funds<br>£<br>400,473<br>(47,382)<br>353,091<br>(14,185)<br>338,906|Transfers<br>between<br>funds<br>£<br>(5,000)<br>5,000<br>-<br>-<br>-|At 30.4.24<br>£<br>4,092,157<br>2,413,817<br>6,505,974<br>175,292<br>6,681,266|
|---|---|---|---|---|



Comparative net movement in funds, included in the above are as follows: 

|**Unrestricted funds**<br>General fund<br>Designated<br>**Restricted funds**<br>Restricted<br>**TOTAL FUNDS**|Incoming<br>resources<br>£<br>4,658,484<br>4,593<br>4,663,077<br>112,128<br>4,775,205|Resources<br>expended<br>£<br>(4,324,001)<br>(51,975)<br>(4,375,976)<br>(126,313)<br>(4,502,289)|Gains and<br>losses<br>£<br>65,990<br>-<br>65,990<br>-<br>65,990|Movement<br>in funds<br>£<br>400,473<br>(47,382)<br>353,091<br>(14,185)<br>338,906|
|---|---|---|---|---|



Page 39 

continued... 



**TAMESIDE & GLOSSOP HOSPICE LIMITED** 

## **NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued for the Period 1 May 2024 to 31 March 2025** 

## **22. EMPLOYEE BENEFIT OBLIGATIONS** 

The Charity operates two pension schemes for staff and these are outlined below: 

## **National Health Service Superannuation Scheme** 

The group is an admitted body for the purposes of the National Health Service Superannuation Scheme. Due to the nature of the scheme there are no separately identifiable assets or liabilities which can be identified  as relating to the Hospice. Therefore, the scheme has been accounted for as a defined contribution scheme. 

The amount of contributions recognised in the statement of financial activity as an expense is £130,382 (2024: £116,990). 

## **Stakeholder Pension Scheme** 

The group supports a Stakeholder Pension Auto-enrolment scheme operated by Standard Life.  Employee contributions are collected by the Hospice and matching employer's contributions are passed on to Standard Life.  All the assets and liabilities are held by Standard Life and there are no separately identifiable assets or liabilities which can be identified as relating to the Hospice. Therefore, the scheme has been accounted for as a defined contribution scheme. 

The amount of contributions recognised in the statement of financial activity as an expense is £77,377 (2024: £77,940). 

## **23. RELATED PARTY DISCLOSURES** 

The charitable company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group. 

There were no related party transactions for the period ended 31 March 2025. 

This page does not form part of the statutory financial statements 

Page 40